Myomo, Inc. (MYO) Q3 2024 Earnings Call Transcript Summary
Myomo, Inc. (MYO) Q3 2024 Earnings Call Transcript Summary
Product revenue accounted for the total quarterly revenue, marking an 81% increase year over year.The following is a summary of the Myomo, Inc. (MYO) Q3 2024 Earnings Call Transcript:
以下是myomo公司（MYO）2024年第三季度業績會議呼叫記錄摘要：
Financial Performance:
財務表現:
Myomo reported a record Q3 2024 revenue of $9.2 million, which is an 83% increase from the previous year.
The Average Selling Price (ASP) of MyoPro units increased to an adjusted $52,700, contributing significantly to revenue growth.
Product revenue accounted for the total quarterly revenue, marking an 81% increase year over year.
myomo報告2024年第三季度創紀錄的營業收入爲920萬美元，較上一年增長83%。
MyoPro裝置的平均售價（ASP）調整後增至52,700美元，對營業收入增長做出了重要貢獻。
產品收入佔據了總季度營業收入的比例，同比增長了81%。
Business Progress:
業務進展:
Myomo has expanded its patient pipeline significantly by 69% year over year, adding 645 new medically qualified candidates.
The company achieved a new record in the backlog with 316 units, representing over $16 million in potential revenue.
Launch of Myomo Academy, an online learning platform for O&P professionals, to enhance training and recruitment of clinicians.
myomo通過逐年增加69%的病人流水線，新增了645位醫學上合格的候選人。
公司在積壓訂單中取得新記錄，達到316台，代表着超過1600萬美元的潛在營業收入。
推出Myomo學院，這是一個面向O&P專業人士的在線學習平台，旨在增強臨床醫師的培訓和招聘。
Opportunities:
機會：
Myomo is capitalizing on Medicare Part B reclassification of MyoPro, improving market access for a wider patient base in the U.S.
The company has started successfully engaging with orthotics and prosthetics (O&P) clinics to increase distribution channels.
Myomo has entered strategic contracts with major payers like Blue Cross Blue Shield of Massachusetts and Paradigm, expanding coverage and market reach.
Myomo正利用美國醫療保險第b部分重新分類MyoPro，改善更廣泛患者群在美國的市場準入。
公司已成功開始與矯形和假肢（O&P）診所合作，以增加分銷渠道。
Myomo已與麻省藍十字藍盾和Paradigm等主要支付方簽訂戰略合同，擴大覆蓋範圍和市場份額。
Risks:
風險：
Delays and challenges with Medicare Advantage plans impacting patient access and care.
Economic pressures and potential operational disruptions could pose risks to supply chain and production capacity.
醫療保險優惠計劃的延遲和挑戰影響了患者的進入和護理。
經濟壓力和潛在的運營中斷可能對供應鏈和生產能力構成風險。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
